Table of Content




1. Research Scope & Methodology
1.1. Study Objectives
1.2. Scope Of Study
1.3. Methodology
1.4. Assumptions & Limitations

2. Executive Summary
2.1. Market Size & Estimates
2.2. Market Overview

3. Market Dynamics
3.1. Key Drivers
3.1.1. Growing Number Of Cancer Cases And Mortalities
3.1.2. Increasing Popularity Of Precision Medicines
3.1.3. Rising Number Of Adverse Drug Reaction Cases
3.2. Key Restraints
3.2.1. Country-Specific Reimbursement Issues
3.2.2. Frequent Cases Of Leakage In Companion Diagnostics For Oncology

4. Key Analytics
4.1. Impact Of Covid-19 On Companion Diagnostics Market
4.2. Key Market Trends
4.3. Porter’S Five Forces Analysis
4.3.1. Buyers Power
4.3.2. Suppliers Power
4.3.3. Substitution
4.3.4. New Entrants
4.3.5. Industry Rivalry
4.4. Opportunity Matrix
4.5. Vendor Landscape
4.6. Value Chain Analysis
4.7. Key Buying Criteria
4.8. Regulatory Framework

5. Market By Technology
5.1. In Situ Hybridization
5.2. Polymerase Chain Reaction
5.3. Immunohistochemistry
5.4. Next Generation Sequencing
5.5. Other Technologies

6. Market By Indication
6.1. Oncology
6.2. Neurology
6.3. Infectious Diseases
6.4. Other Indications

7. Market By End-User
7.1. Pharmaceutical And Biopharmaceutical Companies
7.2. Reference Laboratories
7.3. Other End-Users

8. Market By Products & Services
8.1. Assay Kits And Reagents
8.2. Software & Services

9. Geographical Analysis
9.1. North America
9.1.1. Market Size & Estimates
9.1.2. Key Growth Enablers
9.1.3. Key Challenges
9.1.4. Key Players
9.1.5. Country Analysis
9.1.5.1. United States
9.1.5.2. Canada

10. Competitive Landscape
10.1. Key Strategic Developments
10.1.1. Mergers & Acquisitions
10.1.2. Product Launches & Developments
10.1.3. Partnerships & Agreements
10.2. Company Profiles
10.2.1. Abbott Laboratories
10.2.2. Agilent
10.2.3. Alamc Group
10.2.4. Arup Laboratories
10.2.5. Biocartis
10.2.6. Biomerieux Sa
10.2.7. Danaher Corporation
10.2.8. Ge Healthcare
10.2.9. Genomic Health
10.2.10. Illumina Inc
10.2.11. Myriad Genetics Inc
10.2.12. Qiagen Nv
10.2.13. Roche Diagnostics
10.2.14. Sysmex Corporation
10.2.15. Thermo Fisher Scientific Inc



List of Figures

List Of Figures
Figure 1: Cdx Leakage
Figure 2: Key Market Trends
Figure 3: Porter’S Five Forces Analysis
Figure 4: Opportunity Matrix
Figure 5: Vendor Landscape
Figure 6: Value Chain Analysis
Figure 7: Fda Guidelines For Cdx Approval
Figure 8: North America Companion Diagnostics Market, Growth Potential, By Technology, In 2021
Figure 9: North America Companion Diagnostics Market, By In Situ Hybridization, 2022-2030 (In $ Million)
Figure 10: North America Companion Diagnostics Market, By Polymerase Chain Reaction, 2022-2030 (In $ Million)
Figure 11: North America Companion Diagnostics Market, By Immunohistochemistry, 2022-2030 (In $ Million)
Figure 12: North America Companion Diagnostics Market, By Next Generation Sequencing, 2022-2030 (In $ Million)
Figure 13: North America Companion Diagnostics Market, By Other Technologies, 2022-2030 (In $ Million)
Figure 14: North America Companion Diagnostics Market, Growth Potential, By Indication, In 2021
Figure 15: North America Companion Diagnostics Market, By Oncology, 2022-2030 (In $ Million)
Figure 16: North America Companion Diagnostics Market, By Neurology, 2022-2030 (In $ Million)
Figure 17: North America Companion Diagnostics Market, By Infectious Diseases, 2022-2030 (In $ Million)
Figure 18: North America Companion Diagnostics Market, By Other Indications, 2022-2030 (In $ Million)
Figure 19: North America Companion Diagnostics Market, Growth Potential, By End-User, In 2021
Figure 20: North America Companion Diagnostics Market, By Pharmaceutical And Biopharmaceutical Companies, 2022-2030 (In $ Million)
Figure 21: North America Companion Diagnostics Market, By Reference Laboratories, 2022-2030 (In $ Million)
Figure 22: North America Companion Diagnostics Market, By Other End-Users, 2022-2030 (In $ Million)
Figure 23: North America Companion Diagnostics Market, Growth Potential, By Products & Services, In 2021
Figure 24: North America Companion Diagnostics Market, By Assay Kits And Reagents, 2022-2030 (In $ Million)
Figure 25: North America Companion Diagnostics Market, By Software & Services, 2022-2030 (In $ Million)
Figure 26: North America Companion Diagnostics Market, Country Outlook, 2021 & 2030 (In %)
Figure 27: United States Companion Diagnostics Market, 2022-2030 (In $ Million)
Figure 28: Canada Companion Diagnostics Market, 2022-2030 (In $ Million)

List of Tables

LIST OF TABLES
TABLE 1: MARKET SNAPSHOT - COMPANION DIAGNOSTICS
TABLE 2: NEW CASES OF CANCER PATIENTS IN 2020
TABLE 3: NORTH AMERICA COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
TABLE 4: NORTH AMERICA COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, FORECAST YEARS, 2022-2030 (IN $ MILLION)
TABLE 5: NORTH AMERICA COMPANION DIAGNOSTICS MARKET, BY INDICATION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
TABLE 6: NORTH AMERICA COMPANION DIAGNOSTICS MARKET, BY INDICATION FORECAST YEARS, 2022-2030 (IN $ MILLION)
TABLE 7: NORTH AMERICA COMPANION DIAGNOSTICS MARKET, BY END-USER, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
TABLE 8: NORTH AMERICA COMPANION DIAGNOSTICS MARKET, BY END-USER, FORECAST YEARS, 2022-2030 (IN $ MILLION)
TABLE 9: NORTH AMERICA COMPANION DIAGNOSTICS MARKET, BY PRODUCTS & SERVICES, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
TABLE 10: NORTH AMERICA COMPANION DIAGNOSTICS MARKET, BY PRODUCTS & SERVICES, FORECAST YEARS, 2022-2030 (IN $ MILLION)
TABLE 11: NORTH AMERICA COMPANION DIAGNOSTICS MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
TABLE 12: NORTH AMERICA COMPANION DIAGNOSTICS MARKET, BY COUNTRY, FORECAST YEARS, 2022-2030 (IN $ MILLION)
TABLE 13: LEADING PLAYERS OPERATING IN NORTH AMERICA COMPANION DIAGNOSTICS MARKET
TABLE 14: LIST OF MERGERS & ACQUISITIONS
TABLE 15: LIST OF PRODUCT LAUNCHES & DEVELOPMENTS
TABLE 16: LIST OF PARTNERSHIPS & AGREEMENTS